Growth hormone therapy improves bone mineral density in children with cerebral palsy: a preliminary pilot study.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The researchers conducted a pilot study to evaluate the effect of 18 months of GH therapy on spinal BMD, linear growth, biochemical markers, and functional measures in children with cerebral palsy.

Who Took Part

PubMed indexes the participants as young children, children and teenagers.

Patients included 12 males with cerebral palsy, ages 4.5-15.4 yr.

How the Study Was Run

In design terms this was a randomized and pilot study.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study would be practical.

The study was a randomized control trial, conducted from 2002-2005 at the University of California, Los Angeles, Orthopedic Hospital's Center for Cerebral Palsy.

What Was Measured

The subject headings attached to it are Biomarkers, Body Height, Bone Density, Bone Development, Cerebral Palsy, Growth Hormone and Intercellular Signaling Peptides and Proteins.

What This Means in Plain Language

The paper is a randomized and pilot study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2007 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.